MHA advises international life sciences business on acquisition of UK-based microbiome organisation
November 1st 2023The Corporate Finance team at MHA has advised Australian ASX listed business Microba Life Sciences on acquiring 100 percent of UK-based microbiome leader Invivo Clinical Ltd, an established microbiome testing business.
The acquisition of Invivo Clinical, based in Stroud, Gloucestershire, will provide Microba with vast access to the entire UK healthcare market which spans private practice and the public NHS environment.
Microba Life Sciences are advancing human health with new solutions developed from the human gut microbiome. With their globally leading microbiome expertise and Invivo’s expanded microbiome test range, there are ample interdependent growth opportunities for the sector.
The team at MHA, led by Transaction Services Lead, Rob Dando, and Tax Partner, Nathan Sutcliffe, provided financial and tax due diligence as well as acquisition, tax structuring and SPA advice.
CFO of Microba, James Heath said: “I am sincerely appreciative of the team at MHA’s work on the Invivo transaction.
“We were all impressed with the thorough nature of the team as well as their nimbleness and commerciality when it was required.
“Thank you especially to both Rob and Nathan, who were instrumental throughout the transaction, jumping on calls at a moment’s notice and working through challenges diligently as they arose. An excellent start to what I hope will be a long and fruitful working relationship between Microba and MHA.”
Find out more
If we can help with your business acquisition strategy, please get in touch with one of our Corporate Finance advisers.